Table 5.

Performance estimates of ROMA and the combined 7MetP+ROMA model for early-stage OvCa in the combined Specimen Set.

	Entire Set
		ROMA	ROMA + 7MetP	Difference	P
	AUC (95% CI)	0.84 (0.79–0.90)	0.87 (0.82–0.93)	0.03 (0.01 to 0.04)	<.001
At 11.4% risk threshold for premenopausal and 29.9% for postmenopausal (same risk as ROMA)	Sensitivity	0.76 (0.69 – 0.82)	0.76 (0.70 – 0.82)	0.00 (−0.04 to 0.05)	.464
	Specificity	0.78 (0.75 – 0.81)	0.89 (0.86 – 0.92)	0.11 (0.08 to 0.14)	<.001
	PPV	0.52 (0.45 – 0.58)	0.68 (0.61 – 0.75)	0.16 (0.11 to 0.21)	<.001
	NPV	0.91 (0.89 – 0.94)	0.92 (0.90 – 0.94)	0.01 (−0.01 to 0.02)	.091

Abbreviations: PPV: positive predictive value; NPV: negative predictive value. P-values for comparison of AUCs represent likelihood ratio tests. Risk threshold corresponding to 11.4% in premenopausal women and 29.9% for postmenopausal were chosen based on reported findings from Ortiz-Munoz and colleagues.(21) 1-sided P-values are reported as we expect that the combined 7MetP+ROMA will yield improved performance estimates compared to ROMA alone.